Reaktionsgleichung
[CH3:1]N1CCN(C2C=CC(NC3C4N(N=CN=4)C(C4C=C(C(N)=O)SC=4)=CN=3)=CC=2)CC1.Br[C:33]1[N:38]2[N:39]=[CH:40][N:41]=[C:37]2[C:36]([NH:42][C:43]2[CH:44]=N[C:46]([N:49]3[CH2:54][CH2:53][N:52]([CH:55]([CH3:57])[CH3:56])[CH2:51][CH2:50]3)=[CH:47][CH:48]=2)=[N:35][CH:34]=1.CC1(C)C(C)(C)OB([C:66]2[CH:67]=[C:68]([C:71]([NH2:73])=[O:72])[O:69][CH:70]=2)O1.C([O-])([O-])=O.[Na+].[Na+]>C1C=CC([P]([Pd]([P](C2C=CC=CC=2)(C2C=CC=CC=2)C2C=CC=CC=2)([P](C2C=CC=CC=2)(C2C=CC=CC=2)C2C=CC=CC=2)[P](C2C=CC=CC=2)(C2C=CC=CC=2)C2C=CC=CC=2)(C2C=CC=CC=2)C2C=CC=CC=2)=CC=1.O1CCOCC1>[CH:55]([N:52]1[CH2:51][CH2:50][N:49]([C:46]2[CH:1]=[CH:44][C:43]([NH:42][C:36]3[C:37]4[N:38]([N:39]=[CH:40][N:41]=4)[C:33]([C:66]4[CH:67]=[C:68]([C:71]([NH2:73])=[O:72])[O:69][CH:70]=4)=[CH:34][N:35]=3)=[CH:48][CH:47]=2)[CH2:54][CH2:53]1)([CH3:56])[CH3:57]Komponenten
7
Edukt 4
Produkt 1
Reagenzien, Katalysatoren, Lösungsmittel 2
Versuchsvorschrift
This compound may be prepared using methods as described for Compound 6, step 4, using 5-bromo-N-(6-(4-isopropylpiperazin-1-yl)pyridin-3-yl)-[1,2,4]triazolo[1,5-a]pyrazin-8-amine (80 mg, 0.21 mmol), 4-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-furan-2-carboxylic acid amide (101 mg, 0.42 mmol), and Pd(PPh3)4 (62 mg, 0.053 mmol) in 1.5M Na2CO3 (aq) (1.143 mL, 1.71 mmol), and dioxane (4 mL). The crude product is purified by silica gel column chromatography eluting with DCM and 97:3 DCM:NH3 (7M in MeOH). The title compound is isolated after trituration with diethyl ether (35.4 mg, 42%). Conversion into the mesylate salt using 1M methanesulfonic acid in MeOH (0.0793 mL) affords the title compound as a solid (35 mg).
Aufarbeitung
- customThis compound may be prepared
- customThe crude product is purified by silica gel column chromatography
- washeluting with DCM and 97:3 DCM
Quellen und Nachweise
- ORD-Eintrag
- ord-a8728b33aed94b09a39d36f9e21449a5
- Quelldatensatz
- uspto-grants-2011_03
- Patentnummer
- US07915256B2
Verknüpfte Notizen
Wird geladen…